Business Today's maiden listing of India's PE and VC funds coincides with a change imperative in the industry.

In a breather for corporate executives embroiled in the 2G scam, the Supreme Court nod led to a spate of bail applications being accepted.

Next year, Glenmark Pharma is likely to have half a dozen compounds in Phase II human trials. Chairman Glenn Saldanha hopes to hit the market with one or more of his drugs between 2015 and 2017. This potential upside is precisely why Glenmark is in Business Today's listing of Tomorrow's Goliaths.SPECIAL: India Inc's rising star companies Other 7 companies in the list:IndiGo | Fortis | Lanco Infratech | Cafe Coffee Day | Nuclear Power Corporation | Axis Bank | iGate

For the family-owned business group, the future hinges on the ability to combine strategic and operational excellence with a constant willingness to change. BT presents a theoretical exposition of how the survival prospects of the family business can be evaluated. A framework.

A Money Today-value research study of the stocks that mutual fund managers stacked up over the past one year.

Citius, Altius, Fortius' could well be the rallying cry of the rupee as it rises swiftly, touches new highs and becomes stronger against the dollar.

Indian stocks were trading lower on Monday, in line with the weakness in Asian markets. All the sector indices were in the red, with automobile and FMCG being weighed down the most.

Investing in select pharma stocks might be the shot in the arm that your portfolio needs in times of a slowdown. The general environment for the pharma industry, particularly for domestic companies, seems positive.

As the inflation rate moves up, key market indices are spiralling downward. Is there a way of making sure that your portfolio is not affected by this rising rate?

Like IT, most pharma funds have underperformed in a booming market. What should the investor do right now — sell, hold or buy? Here are some answers.

Using a simple style, this ambitious book aims to help lay investors overcome their fear of learning the basics of mutual funds. Though targeted at a US audience the book is useful to Indian readers too.

This selection of research reports gives information and opinions on companies and industries.They are often filled with jargon, which we must reluctantly inflict on readers sincethe excerpts are verbatim. Seven such terms occur in these extracts: EBITDA = EarningsBefore Interest,Tax, Depreciation,Amortisation, EV = Enterprise Value, EPS = Earnings Per Share, PE = Price-Earnings, PAT/PBT = Profit After/ Before Tax,YoY = Year-on-year.

Piramal's domestic formulations business becomes the latest—and most expensive—acquisition of an Indian drug business by a global pharma major. As the stakes get higher, who's next?

The Orchid Chemicals and Pharmaceuticals and Hospira Inc. deal for the purchase of the former's generic injectable pharmaceuticals business will benefit both parties.

The pharma high flier has been hammered by derivative losses and is choking on a mountain of debt. The good news: Some deft financial restructuring has given both promoter and industry hope.

M&M eyes more auto segments, and more markets. he company is likely to launch the Scorpio in the US through a Georgiabased distributor named Global Vehicles.

Risen: By 38.6 per cent, direct tax collections during the first quarter of 2008-09, to Rs 57,373 crore, compared to 28 per cent and Rs 41,391 crore for the corresponding period last year.

A year ago in late May 2007, Mumbai-headquartered Sun Pharma, together with its subsidiaries, had signed 'definitive agreements' to acquire Taro Pharmaceutical Industries, a multinational manufacturer of generic pharmaceuticals. A year later, the transaction is in tatters and both parties are washing dirty linen in public. Why? T.V. Mahalingam finds out the reasons.

On the fringes of Mumbai, in what’s known as Navi or New Mumbai, lies Mahape. One of the 226-odd functional industrial areas chalked out by the Maharashtra Industrial Corporation (MIDC) in the state is sprawled over this suburb.

Taking advantage of an upbeat economy the central government has launched or revamped major schemes aimed at rural India. But have they really worked for the aam aadmi? Shalini S. Dagar finds out.